Clinical Trials Logo

Conjunctivitis clinical trials

View clinical trials related to Conjunctivitis.

Filter by:

NCT ID: NCT01175590 Completed - Clinical trials for Bacterial Conjunctivitis

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Start date: June 2010
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.

NCT ID: NCT01174823 Completed - Clinical trials for Allergic Conjunctivitis

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

Start date: June 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.

NCT ID: NCT01159769 Completed - Clinical trials for Allergic Conjunctivitis

Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

Start date: June 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

NCT ID: NCT01159015 Completed - Clinical trials for Allergic Conjunctivitis

Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers

Start date: July 2010
Phase: Phase 3
Study type: Interventional

This study is being conducted to evaluate the safety of KetoNaph ophthalmic solution in healthy adult subjects and in pediatric subjects with a history or family history of ocular allergy.

NCT ID: NCT01155999 Completed - Clinical trials for Purulent Bacterial Conjunctivitis

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Start date: December 2008
Phase: Phase 3
Study type: Interventional

Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.

NCT ID: NCT01144429 Completed - Clinical trials for Immunotherapy, Allergen

Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Specific immunotherapy for subcutaneous application: Dose finding study to evaluate the correct dose. 4 concentrations of a birch pollen allergen extract are applied in this study. Duration of therapy 20 weeks. Primary criterion is the Conjunctival Provocation Test (CPT), i.e. comparison between treatment arms of increased amount of quantities of allergen to provoke a positive CPT at the end of treatment.

NCT ID: NCT01134328 Completed - Clinical trials for Allergic Conjunctivitis

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in Enviro-CAC™ Model.

NCT ID: NCT01120132 Completed - Clinical trials for Allergic Conjunctivitis

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.

NCT ID: NCT01119287 Completed - Clinical trials for Allergic Conjunctivitis

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

Start date: March 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).

NCT ID: NCT01111279 Completed - Clinical trials for Seasonal Allergic Rhinoconjunctivitis

Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen allergic patients.